Celgene Acquisition Investor Information

Transaction Update

​​​​August 26, 2019

Bristol-Myers Squibb Announces Agreement Between Celgene and Amgen to Divest OTEZLA® for $13.4 Billion
Press Release​​​​​

​​​​July 29, 2019

Bristol-Myers Squibb Announces European Commission Approval of Pending Acquisition of Celgene
Press Release​​​​​

​​​​June 24, 2019

Bristol-Myers Squibb Provides Update on Pending Merger with Celgene
Press Release​​​​​

​​​​June 5, 2019

Bristol-Myers Squibb Announces Post-Closing Leadership Team
Press Release​​​​​

​​​​April 12, 2019

Bristol-Myers Squibb Shareholders Approve Celgene Acquisition
Press Release​​​​​

​​​​March 29, 2019

Bristol-Myers Squibb Issues Statement on Celgene’s Settlement with Alvogen on Revlimid® Patent Litigation
Press Release​​​​​

​​​​March 29, 2019

Independent Proxy Advisory Firms ISS and Glass Lewis Recommend Bristol-Myers Squibb Shareholders Vote “FOR” Proposed Merger with Celgene
Press Release​​​​​

​​​​March 25, 2019

Bristol-Myers Squibb Board of Directors Sends Letter to Shareholders Highlighting the Compelling Strategic and Financial Rationale of the Celgene Transaction; Company Provides Additional Investor Materials
Press Release​​​​​
​​​​​​​​Letter to Shareholders​​​
Investor Presentation​​​​​
Fact Sheet​​​

​​​​March 19, 2019

Bristol-Myers Squibb Files Investor Presentation Highlighting Significant Benefits of Pending Transaction with Celgene​​
​​​​​​​​​​​Press Release​​​
Investor Presentation​​​​​

​​​​March 6, 2019

Bristol-Myers Squibb Files Investor Presentation and Board of Directors Sends Letter to Shareholders Regarding Pending Transaction with Celgene
​​​Press Release​​​
Letter to Shareholders​​​
Investor Presentation​​​

​​​​February 28, 2019

Bristol-Myers Squibb Issues Statement in Response to Starboard’s Letter 
​​​Press Release​​​​

​​​​February 22, 2019

Bristol-Myers Squibb Announces Filing of Definitive Proxy Statement in Connection with Proposed Merger with Celgene 
​​​Press Release​​​

​​​​February 20, 2019

Bristol-Myers Squibb Provides Update on Pending Transaction with Celgene 
​​​Press Release​​​​​
Investor Presentation​​​​

​​​​January 3, 2019

Bristol-Myers Squibb to Acquire Celgene to Create a Premier Innovative Biopharma Company
​​​Press Release​​
Investor Presentation​

Other Information

Information on the Bristol-Myers Squibb and Celgene Transaction

Information on the Bristol-Myers Squibb and Celgene Transaction

Learn more about Bristol-Myers Squibb’s planned acquisition of Celgene.